 |
| (사진=휴젤) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] A major shareholder of Hugel, a botulinum toxin manufacturer, is reportedly considering making an open purchase after attracting more than 500 billion won in investment to expand its overseas business.
According to the investment banking (IB) industry on the 6th, Aphrodite Acquisition Holding, huge shareholder of Hugel, is discussing attracting investment with global private equity funds (PEF) through Morgan Stanley and Moalis. Aphrodite is a special purpose corporation (SPC) established by a consortium of investors such as GS, which acquired Hugel in 2021.
The investment attraction is believed to include the sale of some old shares while weighing on the issuance of new shares through paid-in capital increase.
In addition to discussions on attracting investment, Hugel is also said to be conducting behind-the-scenes coordination with local securities firms to select an open buyer. Major shareholders of Hugel, a consortium, are trying to secure solid management rights by buying at least 50% + 1 share ahead of the introduction of the mandatory tender offer system.
In August 2021, Hugel signed a 1.7239 trillion won stock trading deal with a consortium of GS-IMM Investment, Singapore-based investment firm C Bridge Capital and UAE sovereign wealth fund Mubadala. Since then, it has completed the acquisition of the remaining stake and currently has a 43.24% stake.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
